Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
UNIVERSITE D'ORLEANS currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are being handled by 2 distinct examiners across 2 distinct art units, which indicates that each pending matter is being treated as a unique technical and administrative case. This distribution requires the university to manage 2 separate prosecution tracks without any overlap in personnel or art unit oversight.
KIFLE, BRUCK is the busiest examiner for the portfolio, currently overseeing 1 pending office action. Because there are 2 pending office actions and 2 distinct examiners, the workload is distributed, with each examiner managing 1 action. This means that the university's success in the biotechnology and pharmaceutical sector is currently split between the independent decisions of these 2 individuals.
The presence of 2 distinct art units for only 2 pending office actions suggests that the university's research is being categorized into different specialized niches within the USPTO. For practitioners, this lack of concentration means that they cannot rely on a single examiner's feedback to guide the entire pending portfolio. Each of the 2 pending office actions must be prosecuted based on the specific requirements of the assigned examiner and the standards of their respective art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIFLE, BRUCK | 1 | 79.3% | +15.8% |
| PUTTLITZ, KARL J | 1 | 69.2% | +18.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18551361 | APPLICATIONS OF BIASED LIGANDS OF THE SEROTONIN 5-HT7 RECEPTOR FOR THE TREATMENT OF PAIN, MULTIPLE SCLEROSIS AND THE CONTROL OF THERMOREGULATION | KIFLE, BRUCK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18551361 | APPLICATIONS OF BIASED LIGANDS OF THE SEROTONIN 5-HT7 RECEPTOR FOR THE TREATMENT OF PAIN, MULTIPLE SCLEROSIS AND THE CONTROL OF THERMOREGULATION | KIFLE, BRUCK | — |
| 18548850 | USE OF A PERIOSTIN ANTIBODY FOR TREATING INFLAMMATION, FIBROSIS AND LUNG DISEASES | PUTTLITZ, KARL J | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18551361 | APPLICATIONS OF BIASED LIGANDS OF THE SEROTONIN 5-HT7 RECEPTOR FOR THE TREATMENT OF PAIN, MULTIPLE SCLEROSIS AND THE CONTROL OF THERMOREGULATION | KIFLE, BRUCK | 1624 | §102§112 | Non-Final OA | — | Pending | Sep 19, 2023 |
| 18548850 | USE OF A PERIOSTIN ANTIBODY FOR TREATING INFLAMMATION, FIBROSIS AND LUNG DISEASES | PUTTLITZ, KARL J | 1646 | §103 | Final Rejection | — | Pending | Sep 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITE D'ORLEANS has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Bruck Kifle has the most, with 1 of UNIVERSITE D'ORLEANS's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
